Figure 2.
Functional characterization of TCF3 variants and their association with clinical features of pediatric B-ALL. (A) Relative μE5/μE2 promoter activity in luciferase reporter assay using HEK293T cells ectopically expressing TCF3–E12 WT or TCF3-E12 variants. TCF3-E47 p.E555K was included as a positive control. The results are represented as the average ± standard deviation of 6 independent experiments. (B) Characteristics of 10 patients with TCF3 germline variant compared with 3799 patients with B-ALL treated in COG P9904/5/6 and COG AALL0332 clinical trials. WBC, white blood count.

Functional characterization of TCF3 variants and their association with clinical features of pediatric B-ALL. (A) Relative μE5/μE2 promoter activity in luciferase reporter assay using HEK293T cells ectopically expressing TCF3–E12 WT or TCF3-E12 variants. TCF3-E47 p.E555K was included as a positive control. The results are represented as the average ± standard deviation of 6 independent experiments. (B) Characteristics of 10 patients with TCF3 germline variant compared with 3799 patients with B-ALL treated in COG P9904/5/6 and COG AALL0332 clinical trials. WBC, white blood count.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal